Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 28 of the 40 sources its claims cite were checked for support.

Pan-cancer landscape of homologous recombination deficiency.

Open access
Nguyen, Luan, W. M. Martens, John, Van Hoeck, Arne, Cuppen, Edwin · 2020 · Nature communications

Published version of a preprint

Abstract

Homologous recombination deficiency (HRD) results in impaired double strand break repair and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar-based pan-cancer Classifier of HOmologous Recombination Deficiency (CHORD) that can discriminate BRCA1- and BRCA2-subtypes. Analysis of a metastatic (n = 3,504) and primary (n = 1,854) pan-cancer cohort reveals that HRD is most frequent in ovarian and breast cancer, followed by pancreatic and prostate cancer. We identify biallelic inactivation of BRCA1, BRCA2, RAD51C or PALB2 as the most common genetic cause of HRD, with RAD51C and PALB2 inactivation resulting in BRCA2-type HRD. We find that while the specific genetic cause of HRD is cancer type specific, biallelic inactivation is predominantly associated with loss-of-heterozygosity (LOH), with increased contribution of deep deletions in prostate cancer. Our results demonstrate the value of pan-cancer genomics-based HRD testing and its potential diagnostic value for patient stratification towards treatment with e.g. poly ADP-ribose polymerase inhibitors (PARPi).

Overview

CoChat Summary

TL;DR

The authors developed CHORD, a random forest classifier that detects homologous recombination deficiency (HRD) and distinguishes BRCA1-type from BRCA2-type HRD using whole-genome mutation contexts across cancers. In 5,122 primary and metastatic patients, HRD was most frequent in ovarian, breast, prostate, and pancreatic cancer, with BRCA1, BRCA2, RAD51C, and PALB2 biallelic inactivation as common genetic causes.

Key findings

  • CHORD achieved high performance in cross-validation (AUROC 0.98, AUPRC 0.87) and in independent BRCA-EU and PCAWG datasets (AUROC >0.98, AUPRC >0.93).
  • Among 5,122 patients (3,504 HMF metastatic and 1,618 PCAWG primary), 310 (6%) were CHORD-HRD: 118 BRCA1-type and 192 BRCA2-type; 4,812 were CHORD-HRP.
  • Biallelic inactivation was significantly enriched in CHORD-HRD vs CHORD-HRP for BRCA1 (q = 9.4e-51), BRCA2 (q = 4.8e-101), RAD51C (q = 5.6e-5), and PALB2 (q = 0.02); RAD51C and PALB2 inactivation produced BRCA2-type HRD.
  • HRD was most prevalent in ovarian, breast, prostate, and pancreatic cancer (85% combined); primary vs metastatic frequencies were ovarian 52% vs 30%, breast 24% vs 12%, prostate 5.6% vs 13%, and pancreatic 7.3% vs 13%.

Methods

  • CHORD is a random forest trained on relative counts of SNV, indel, and structural variant mutation contexts from 3,824 HMF metastatic tumors; 2,026 samples (53%) were used for training, including 35 BRCA1-deficient, 89 BRCA2-deficient, and 1,902 BRCA1/2-proficient samples.
  • Performance was assessed by 10-fold nested cross-validation and by application to BRCA-EU (543 primary breast tumors; 365 used for HRDetect) and PCAWG (1,854 primary tumors; 1,172 selected for validation).
  • For pan-cancer analysis, CHORD was applied to HMF and PCAWG samples passing QC; genetic causes were assessed by biallelic status of 781 cancer/HR-related genes, Fisher’s exact enrichment tests, and clustering of CHORD-HRD samples.

Limitations

  • The paper states that primary vs metastatic HRD rate differences may be confounded by patient inclusion criteria, and that methylation data were unavailable for HMF and PCAWG, preventing direct assessment of promoter methylation as an HRD cause.
  • The authors note that mutational scars reflect genomic history rather than ongoing processes, so false-positive CHORD predictions are possible (e.g., HRD reversion, recent HRD acquisition, or radiotherapy-associated microhomology deletions); subclonal predictions should be interpreted cautiously.
  • The paper states that variant calling pipeline differences can affect CHORD, additional validation/threshold optimization is recommended for other pipelines, and low numbers of BRCA1/2-deficient samples in some cancer types may make error estimates and HRD frequency underestimates uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19406-4

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 CHORD is a random forest Classifier of HOmologous Recombination Deficiency able to distinguish between BRCA1- and BRCA2-type HRD phenotypes in a pan-cancer context. a The features used for training CHORD are relative counts of different mutation contexts, which fall into one of three groups based on mutation type. (i) Single nucleotide variants (SNV): six possible base substitutions (C > A, C > G, C > T, T > A, T > C, T > G). (ii) Indels: indels with flanking microhomology (del.mh, ins.mh), within repeat regions (del.rep, del.none), or not falling into either of these 2 categories (del.none, ins.none). (iii) Structural variants (SV): SVs stratified by type and length. Relative counts were calculated separately for each of the 3 mutation types. b Training and application of CHORD. From a total of 3,824 metastatic tumor samples, 2026 samples were selected for training CHORD. The model outputs the probability of BRCA1-type HRD and BRCA2-type HRD, with the probability of HRD being the sum of these 2 probabilities. The performance of CHORD was assessed via a 10-fold nested cross-validation (CV) procedure on the training samples, as well as by applying the model to the BRCA-EU dataset (543 primary breast tumors) and PCAWG dataset (1,854 primary tumors). Lastly, CHORD was applied to all samples in the HMF and PCAWG dataset in order to gain insights into the pan-cancer landscape of HRD. c The features used by CHORD to predict HRD as well as BRCA1-type HRD and BRCA2-type HRD, with their importance indicated by mean decrease in accuracy. Deletions with 2 to ≥5 bp (i.e. ≥2 bp) of flanking microhomology (del.mh.bimh.2.5) was the most important feature for predicting HRD as a whole, with 1–100 kb structural duplications (DUP_1e03_1e04_bp, DUP_1e04_1e05_bp) differentiating BRCA1-type HRD from BRCA2-type HRD. Boxplot and dots (n = 10) show the feature importance over 10-folds of nested CV on the training set, with the red line showing the feature importance in the final CHORD model. Boxes show the interquartile range (IQR) and whiskers show the largest/smallest values within 1.5 times the IQR.
Fig. 1 CHORD is a random forest Classifier of HOmologous Recombination Deficiency able to distinguish between BRCA1- and BRCA2-type HRD phenotypes in a pan-cancer context. a The features used for training CHORD are relative counts of different mutation contexts, which fall into one of three groups based on mutation type. (i) Single nucleotide variants (SNV): six possible base substitutions (C > A, C > G, C > T, T > A, T > C, T > G). (ii) Indels: indels with flanking microhomology (del.mh, ins.mh), within repeat regions (del.rep, del.none), or not falling into either of these 2 categories (del.none, ins.none). (iii) Structural variants (SV): SVs stratified by type and length. Relative counts were calculated separately for each of the 3 mutation types. b Training and application of CHORD. From a total of 3,824 metastatic tumor samples, 2026 samples were selected for training CHORD. The model outputs the probability of BRCA1-type HRD and BRCA2-type HRD, with the probability of HRD being the sum of these 2 probabilities. The performance of CHORD was assessed via a 10-fold nested cross-validation (CV) procedure on the training samples, as well as by applying the model to the BRCA-EU dataset (543 primary breast tumors) and PCAWG dataset (1,854 primary tumors). Lastly, CHORD was applied to all samples in the HMF and PCAWG dataset in order to gain insights into the pan-cancer landscape of HRD. c The features used by CHORD to predict HRD as well as BRCA1-type HRD and BRCA2-type HRD, with their importance indicated by mean decrease in accuracy. Deletions with 2 to ≥5 bp (i.e. ≥2 bp) of flanking microhomology (del.mh.bimh.2.5) was the most important feature for predicting HRD as a whole, with 1–100 kb structural duplications (DUP_1e03_1e04_bp, DUP_1e04_1e05_bp) differentiating BRCA1-type HRD from BRCA2-type HRD. Boxplot and dots (n = 10) show the feature importance over 10-folds of nested CV on the training set, with the red line showing the feature importance in the final CHORD model. Boxes show the interquartile range (IQR) and whiskers show the largest/smallest values within 1.5 times the IQR.CC BY · PubMed Central
Fig. 2 Performance of CHORD. Performance was determined by 10-fold cross-validation (CV) on the HMF training data, as well as prediction on two independent datasets: BRCA-EU (primary breast cancer dataset) and PCAWG (primary pan-cancer dataset). BRCA-EU and PCAWG samples shown here all passed CHORD’s QC criteria (i.e. MSI absent, ≥50 indels, ≥30 SVs if a sample was predicted HRD). a, d, g The probability of HRD for each sample (total bar height) with each bar being divided into segments indicating the probability of BRCA1- (orange) and BRCA2-type HRD (purple). Stripes below the bar plot indicate biallelic loss of BRCA1 or BRCA2. In a, probabilities have been aggregated from the 10 CV folds. b, e, h Receiver operating characteristic (ROC) and c, f, i precision-recall curves (PR) and respective area under the curve (AUC) values showing the performance of CHORD when predicting HRD as a whole (gray), BRCA1-type HRD (orange), or BRCA2-type HRD (purple).
Fig. 2 Performance of CHORD. Performance was determined by 10-fold cross-validation (CV) on the HMF training data, as well as prediction on two independent datasets: BRCA-EU (primary breast cancer dataset) and PCAWG (primary pan-cancer dataset). BRCA-EU and PCAWG samples shown here all passed CHORD’s QC criteria (i.e. MSI absent, ≥50 indels, ≥30 SVs if a sample was predicted HRD). a, d, g The probability of HRD for each sample (total bar height) with each bar being divided into segments indicating the probability of BRCA1- (orange) and BRCA2-type HRD (purple). Stripes below the bar plot indicate biallelic loss of BRCA1 or BRCA2. In a, probabilities have been aggregated from the 10 CV folds. b, e, h Receiver operating characteristic (ROC) and c, f, i precision-recall curves (PR) and respective area under the curve (AUC) values showing the performance of CHORD when predicting HRD as a whole (gray), BRCA1-type HRD (orange), or BRCA2-type HRD (purple).CC BY · PubMed Central
Fig. 3 The genetic causes of HRD in patients from the HMF and PCAWG datasets. a The bar plot shows the probability of HRD for each patient (total bar height) with each bar being divided into segments indicating the probability of BRCA1-type HRD (orange) and BRCA2-type HRD (purple). 310 patients were predicted HRD while 4812 were predicted HRP by CHORD. b A one-tailed Fisher’s exact test identified enrichment of BRCA1 (q = 9.4e-51), BRCA2 (q = 4.8e-101), RAD51C (q = 5.6e-5) and PALB2 (q = 0.02) biallelic inactivation in CHORD-HRD vs. CHORD-HRP patients (from a list of 781 cancer and HR related genes). Each point represents a gene with its size/color corresponding to the statistical significance as determined by the Fisher’s exact test, with axes indicating the percentage of patients (within either the CHORD-HRD or CHORD-HRP group) in which biallelic inactivation was detected. Multiple testing correction was performed using the Hochberg procedure. c Biallelic inactivation of BRCA2, RAD51C and PALB2 was associated with BRCA2-type HRD, whereas only BRCA1 inactivation was associated with BRCA1-type HRD. Top: BRCA1- and BRCA2-type HRD probabilities from CHORD. Middle: SV contexts (duplications 1–10 kb and 10–100 kb) used by CHORD to distinguish BRCA1- from BRCA2-type HRD. Bottom: The biallelic status of each gene. Samples were clustered according to HRD subtype, and by the impact of a biallelic/monoallelic event (based on ‘P-scores’ as detailed in the methods). Clusters 1, 2, 3, and 5 correspond to patients with identified inactivation of BRCA2, RAD51C, PALB2 and BRCA1, while clusters 4 and 6 correspond to patients without clear biallelic inactivation of these 4 genes. Tiles marked as “Known pathogenic” refer to variants having a “pathogenic” or “likely pathogenic” annotation in ClinVar. “Other” variants include various low impact variants such as splice region variants or intron variants (these are fully specified in Supplementary Data 4). LOH: loss-of-heterozygosity. Only data from samples that passed CHORD’s QC criteria are shown in this figure (MSI absent, ≥50 indels, and ≥30 SVs if a sample was predicted HRD).
Fig. 3 The genetic causes of HRD in patients from the HMF and PCAWG datasets. a The bar plot shows the probability of HRD for each patient (total bar height) with each bar being divided into segments indicating the probability of BRCA1-type HRD (orange) and BRCA2-type HRD (purple). 310 patients were predicted HRD while 4812 were predicted HRP by CHORD. b A one-tailed Fisher’s exact test identified enrichment of BRCA1 (q = 9.4e-51), BRCA2 (q = 4.8e-101), RAD51C (q = 5.6e-5) and PALB2 (q = 0.02) biallelic inactivation in CHORD-HRD vs. CHORD-HRP patients (from a list of 781 cancer and HR related genes). Each point represents a gene with its size/color corresponding to the statistical significance as determined by the Fisher’s exact test, with axes indicating the percentage of patients (within either the CHORD-HRD or CHORD-HRP group) in which biallelic inactivation was detected. Multiple testing correction was performed using the Hochberg procedure. c Biallelic inactivation of BRCA2, RAD51C and PALB2 was associated with BRCA2-type HRD, whereas only BRCA1 inactivation was associated with BRCA1-type HRD. Top: BRCA1- and BRCA2-type HRD probabilities from CHORD. Middle: SV contexts (duplications 1–10 kb and 10–100 kb) used by CHORD to distinguish BRCA1- from BRCA2-type HRD. Bottom: The biallelic status of each gene. Samples were clustered according to HRD subtype, and by the impact of a biallelic/monoallelic event (based on ‘P-scores’ as detailed in the methods). Clusters 1, 2, 3, and 5 correspond to patients with identified inactivation of BRCA2, RAD51C, PALB2 and BRCA1, while clusters 4 and 6 correspond to patients without clear biallelic inactivation of these 4 genes. Tiles marked as “Known pathogenic” refer to variants having a “pathogenic” or “likely pathogenic” annotation in ClinVar. “Other” variants include various low impact variants such as splice region variants or intron variants (these are fully specified in Supplementary Data 4). LOH: loss-of-heterozygosity. Only data from samples that passed CHORD’s QC criteria are shown in this figure (MSI absent, ≥50 indels, and ≥30 SVs if a sample was predicted HRD).CC BY · PubMed Central
Fig. 4 Percentage breakdown of the incidence and genetic causes of HRD in CHORD-HRD patients pan-cancer and by cancer type. Left and right bars represent the HMF and PCAWG datasets respectively. The vertical split in the figure separates cancer types with (left side) and without (right side) ≥10 CHORD-HRD patients in at least one of the datasets. a Frequency of HRD. Cancer types where no frequency of HRD is displayed contain no data in either the HMF or PCAWG datasets. b The gene deficiency associated with HRD. Bar segments are grouped into BRCA2-type HRD genes (BRCA2, RAD51C, PALB2) and BRCA1-type HRD genes (BRCA1 only). c The likely combination of biallelic events in BRCA1/2, RAD51C or PALB2 causing HRD. d Whether the genetic cause of HRD was purely due to somatic events, due to germline predisposition, or unknown. In c, d, “Unknown” and/or “LOH + unknown” bar segments refer to patients where no clear biallelic loss of the aforementioned BRCA1/2, RAD51C, or PALB2 was identified (i.e. clusters 4 and 6 of Fig. 3c). LOH: loss-of-heterozygosity. Only data from samples that passed CHORD’s QC criteria are shown in this figure (MSI absent, ≥50 indels, and ≥30 SVs if a sample was predicted HRD).
Fig. 4 Percentage breakdown of the incidence and genetic causes of HRD in CHORD-HRD patients pan-cancer and by cancer type. Left and right bars represent the HMF and PCAWG datasets respectively. The vertical split in the figure separates cancer types with (left side) and without (right side) ≥10 CHORD-HRD patients in at least one of the datasets. a Frequency of HRD. Cancer types where no frequency of HRD is displayed contain no data in either the HMF or PCAWG datasets. b The gene deficiency associated with HRD. Bar segments are grouped into BRCA2-type HRD genes (BRCA2, RAD51C, PALB2) and BRCA1-type HRD genes (BRCA1 only). c The likely combination of biallelic events in BRCA1/2, RAD51C or PALB2 causing HRD. d Whether the genetic cause of HRD was purely due to somatic events, due to germline predisposition, or unknown. In c, d, “Unknown” and/or “LOH + unknown” bar segments refer to patients where no clear biallelic loss of the aforementioned BRCA1/2, RAD51C, or PALB2 was identified (i.e. clusters 4 and 6 of Fig. 3c). LOH: loss-of-heterozygosity. Only data from samples that passed CHORD’s QC criteria are shown in this figure (MSI absent, ≥50 indels, and ≥30 SVs if a sample was predicted HRD).CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 7 Not valid · 9 Not checked · 71 Own results and interpretations

62 more claims · 8 with their cited sources checked

Create a free account to see all 102 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 48 references

Cited by

See all 547

Metadata

Authors
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E.
Affiliations
University Medical Center Utrecht (NL)
Corresponding author
Cuppen, Edwin
Venue
Nature communications
Published
2020-11-04
Volume
11
Issue
1
Pages
5584-5584
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3095003868
Cited by
532
References
48
Citations by year
2026: 58 · 2025: 99 · 2024: 101 · 2023: 100 · 2022: 108 · 2021: 63 · 2020: 3
FWCI
43.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.001.028)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
homologous recombination deficiency, pan-cancer, BRCA1, BRCA2, RAD51C, PALB2, biallelic inactivation, loss of heterozygosity, DNA double-strand break repair, ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, PARP inhibitors, patient stratification, metastatic cancer
MeSH terms
Fanconi Anemia Complementation Group N Protein, Alleles, Breast Neoplasms, DNA-Binding Proteins, Female, Multigene Family, Humans, Male, Mutation, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Incidence, BRCA1 Protein, Loss of Heterozygosity, Genomics, BRCA2 Protein, Databases, Genetic, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pan-cancer landscape of homologous recombination deficiency. https://app.cochat.ai/papers/10.1038/s41467-020-19406-4
The paper
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020). Pan-cancer landscape of homologous recombination deficiency. Nature communications. https://doi.org/10.1038/s41467-020-19406-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.